Yes, but they had failed a number of lines (median was three), so the safety was acceptable. They already have an ongoing (registration-directed) PhII in esophageal and esophagogastric junction, with another (for ovarian) planned this year. If you take the latter, the ORR so far is 36% and DCR is 86%, while the current ORR for existing therapies in platinum-resistant disease is under 13%.
Market Data 
Markets 
